P16INK4a gene promoter methylation as a biomarker for the analysis of non-small cell lung most cancers: An up to date meta-analysis.
Thorac Most cancers. 2018 Jun 21;:
Authors: Tuo L, Sha S, Huayu Z, Du Okay
BACKGROUND: This meta-analysis was carried out to analyze the diagnostic efficiency of P16INK4a gene promoter methylation as a biomarker of non-small cell lung most cancers (NSCLC).
METHODS: Two reviewers independently searched the Net of Science, PubMed, Cochrane, Embase, China Nationwide Information Infrastructure, and Chinese language Biomedical Literature databases. Publications related to P16INK4a gene promoter methylation in serum or bronchoalveolar fluid/sputum have been screened and included on this meta-analysis. Pooled diagnostic sensitivity, specificity, and symmetric receiver working attribute curve have been calculated.
RESULTS: Twenty-six publications with 1768 lung most cancers circumstances and 1323 controls have been included. The pooled sensitivity, specificity, optimistic and adverse chance ratios, and diagnostic odds ratio have been Zero.46 (95% confidence interval [CI] Zero.43-Zero.48), Zero.90 (95% CI Zero.88-Zero.91), 6.33 (95% CI three.89-10.30), Zero.57 (95% CI Zero.50-Zero.65) and 10.72 (95% CI 6.94-16.56), respectively, for P16INK4a gene promoter methylation as a biomarker for the analysis of NSCLC. The world underneath the symmetric receiver working attribute curve was Zero.75 with a typical error of Zero.004. No publication bias was detected through line regression check (t?=?Zero.95; P?=?Zero.35) and Begg’s funnel plot.
CONCLUSION: P16INK4a gene promoter methylation detection in serum or bronchoalveolar fluid/sputum could also be a possible biomarker for NSCLC analysis; nonetheless, the sensitivity was comparatively low, which isn’t appropriate for NSCLC screening.
PMID: 29927090 [PubMed – as supplied by publisher]